Novo Nordisk A/S (VIE:NNO2)
Austria
· Delayed Price · Currency is EUR | Market Cap | 141.54B |
| Revenue (ttm) | 41.38B |
| Net Income (ttm) | 13.72B |
| Shares Out | n/a |
| EPS (ttm) | 3.08 |
| PE Ratio | 10.32 |
| Forward PE | 11.35 |
| Dividend | 1.56 (5.04%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 4,762 |
| Average Volume | 11,810 |
| Open | 32.04 |
| Previous Close | 32.06 |
| Day's Range | 31.00 - 32.04 |
| 52-Week Range | 31.00 - 86.87 |
| Beta | n/a |
| RSI | 22.95 |
| Earnings Date | Feb 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk (NVO) Faces Tough Month Amid Competitive Pressures
Novo Nordisk (NVO) Faces Tough Month Amid Competitive Pressures
Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. Nvidia (NASDAQ: NVDA) reported blockbuster fourth-quarter earnings, ...
Anthropic vs. The Pentagon: what enterprises should do
The relationship between one of Silicon Valley's most lucrative and powerful AI model makers, Anthropic, and the U.S. government reached a breaking point on Friday, February 27, 2026. President Donald...
FDA Approves Novo Nordisk's Sogroya for New Pediatric Indications (NVO)
FDA Approves Novo Nordisk's Sogroya for New Pediatric Indications (NVO)
Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival
Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival
Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
Novo Nordisk is repriced as if its fundamentals have sharply deteriorated, despite strong underlying demand and market expansion drivers. NVO projects a 5-13% decline in 2026 sales and profits, mainly...
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.
Novo Nordisk: A Trap, Not A Trade (Rating Upgrade)
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Altimmune and Novo Nordisk have encountered some headwinds in recent years. Both could rebound, but one of them looks far more likely to do so.
Why Shares of Novo Nordisk Stock Sank (Again) This Week
Novo Nordisk lost another head-to-head trial against Eli Lilly. The company is cutting prices on weight-loss drugs in 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to c...
Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade)
Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade)
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Expand NYSE: NVO Novo Nordisk Today's Change (-1.11%) $-0.43 Current Price $38.16 Key Data Points Market Cap $130B Day's Range $37.65 - $38.24 52wk Range $37.65 - $91.90 Volume 55M Avg Vol 22M Gross M...
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash
The big news around Novo Nordisk for the past couple of years has been about GLP-1 drugs. Looking back in its history, however, the longer-term story is about its role in treating diabetes.
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment
But beneath the selloff, something unusual has emerged.
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment
Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset. ... Full story available on Benzinga.com
Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs
Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ...
Novo Nordisk (NVO) Enters $2.1B Partnership with Vivtex for Oral Drugs
Novo Nordisk (NVO) Enters $2.1B Partnership with Vivtex for Oral Drugs
Ozempic Price War - Novo Nordisk Slashes Prices By 50%
Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday's premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S....
Ozempic Price War - Novo Nordisk Slashes Prices By 50%
Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S...
Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion
The pharma giant will license drug-delivery technologies from Vivtex to develop next-generation oral medicines for obesity, diabetes and associated diseases.
Novo Nordisk (NVO) Partners with Vivtex for Oral Biologics Development
Novo Nordisk (NVO) Partners with Vivtex for Oral Biologics Development
Novo Nordisk Partners Vivtex To Develop Next-generation Oral Medicines For Obesity And Diabetes
(RTTNews) - Danish drugmaker Novo Nordisk and biotechnology company Vivtex Corp. announced Wednesday a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associat...
Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesd...